- ►nih.gov - Free from Publisher C Hopley, G Salkeld, JJ Wang, P Mitchell - British Journal of Ophthalmology, 2004 - bjo.bmj.com Methods: A cost utility analysis (CUA) was conducted to estimate the cost per
quality adjusted life year (QALY) for screening a cohort of men and women, aged
55 years and over, for early AMD and then treating them with zinc and ... Cited by 29 - Related articles - BL Direct - All 8 versions
BG Busbee, MM Brown, GC Brown, S Sharma - Retina, 2003 - journals.lww.com *Doctor, Center for Value-Based Medicine, and Department of Ophthalmology, Tufts
New England Medical Center. †Director, Center for Value-Based Medicine,
Flourtown, and Cataract and Primary Eye Care Service, Wills Eye Hospital. ... Cited by 23 - Related articles - BL Direct
J Trevithick, D Massel, J Robertson, S Tomany … - Neuro-Ophthalmology, 2004 - informahealthcare.com Correspondence and reprint requests to: John R. Trevithick Dept. Biochemistry
Univ. Western Ontario London, Ontario Canada E-mail: trevjohn@uwo.ca ...
Acknowledgements: Drug cost estimates were kindly provided by Bruce Merritt ... Cited by 7 - Related articles - All 4 versions
- ►nih.gov - Free from Publisher C Hopley, G Salkeld, P Mitchell - British journal of ophthalmology, 2004 - bjo.bmj.com Methods: Cost utility analysis (CUA) was conducted to estimate the cost
effectiveness of PDT for scenarios involving reasonable (6/12) and poor (6/60)
visual acuity. The models incorporated data from the Treatment of ... Cited by 38 - Related articles - BL Direct - All 8 versions
- ►nih.gov - Free from Publisher DH Smith, P Fenn, M Drummond - British Journal of Ophthalmology, 2004 - bjo.bmj.com Results: From the government perspective, over the 2 year period, the expected
incremental cost effectiveness ratios range from £286 000 (starting VA 20/100)
to £76 000 (starting VA 20/40) per QALY gained and from £14 000 (20/100) ... Cited by 43 - Related articles - BL Direct - All 11 versions
C Meads, C Salas, T Roberts, D Moore, A Fry … - Health Technol Assess, 2003 - hta.nhs.uk Age-related macular degeneration (AMD) is a major cause of blindness affecting
the central portion of the retina (the macula). Wet AMD is one form of the
condition and involves the formation of neovascular membranes. It is ... Cited by 45 - Related articles - All 4 versions
SSBJS SM, CDS GK - Canadian Journal of Ophthalmology, 2005 - 万方数据资源系统 Objective: Health economic models can assist policy-makers in determining the
value of novel treatments from the viewpoint of society. In this context, value
is defined as the benefit of treatment, given its cost. A new treatment for ... Cited by 9 - Related articles - All 4 versions
CHMBCB MBA, RCMAS PhD, PMMDPD … - Clinical & Experimental Ophthalmology - interscience.wiley.com The purpose of this report was to: (i) outline the potential value of health
economic studies into age-related macular degeneration (AMD); (ii) provide an
overview of health economic studies pertinent to AMD; and (iii) outline the ... Cited by 10 - Related articles - BL Direct - All 3 versions
RA Greiner - Seminars in Ophthalmology, 2001 - informahealthcare.com The cost-effectiveness of photodynamic therapy with verteporfin in the treatment
of patients with predominantly classic subfoveal choroidal neovascularization
secondary to age-related macular degeneration was investigated by a Markov ... Cited by 15 - Related articles - BL Direct - All 6 versions
